Ann: Continued promising results in PTX-100 TCL trial, page-44

I would be so happy if that happens. Lets hope that PTX can get the meeting with FDA later in the year as they will be requesting. PTX must have very compelling data which they will present and will ask the regulators to review and discuss the best pathway to take this treatment forward for TCL. From what I have read the prognosis for TCL is worse than BCL (B Cell Lymphomas) but not much treatment options. In fact only palliative care is currently available for CTCL. With this in mind it's very important for us to wait for the outcome of the FDA meeting. I am extremely hopeful that FDA won't take long to approve this product if safety and efficacy continue to be as good as this announcement.